Please Wait
Applying Filters...
menu
    • menu
    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    CT1812

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cognition Therapeutics Completes CT1812 Enrollment in DLB Trial
    Cognition Therapeutics Completes CT1812 Enrollment in DLB Trial

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3198763/0/en/Cognition-Therapeutics-Reaches-Full-Enrollment-in-Expanded-Access-Program-for-Zervimesine-CT1812-in-Dementia-with-Lewy-Bodies.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share
    Cognition Therapeutics Unveils Zervimesine Phase 3 Plan in AD
    Cognition Therapeutics Unveils Zervimesine Phase 3 Plan in AD

    01 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/01/3196911/0/en/Cognition-Therapeutics-Presents-Phase-3-Plan-for-Zervimesine-CT1812-in-Alzheimer-s-Disease-at-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-Conference.html

    GLOBENEWSWIRE
    01 Dec 2025
    Share Share
    Cognition Completes Enrollment in Phase 2 Study of Zervimesine
    Cognition Completes Enrollment in Phase 2 Study of Zervimesine

    13 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/13/3187212/0/en/Cognition-Therapeutics-Completes-Enrollment-in-Phase-2-Study-of-Zervimesine-CT1812-in-Early-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    13 Nov 2025
    Share Share
    Cognition Therapeutics Wraps up FDA Meeting for Zervimesine
    Cognition Therapeutics Wraps up FDA Meeting for Zervimesine

    10 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/10/3113149/0/en/Cognition-Therapeutics-Completes-End-of-Phase-2-Meeting-with-FDA-for-Zervimesine-CT1812-in-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    10 Jul 2025
    Share Share
    Cognition Therapeutics' CT1812 Study Results Accepted For AAIC Presentation
    Cognition Therapeutics' CT1812 Study Results Accepted For AAIC Presentation

    02 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/02/2907325/0/en/Results-from-Cognition-Therapeutics-Phase-2-SHINE-Study-of-CT1812-in-Mild-to-Moderate-Alzheimer-s-Disease-Accepted-for-Presentation-at-AAIC.html

    GLOBENEWSWIRE
    02 Jul 2024
    Share Share
    Cognition Completes Enrollment in SHIMMER Phase 2 for DLB
    Cognition Completes Enrollment in SHIMMER Phase 2 for DLB

    29 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/29/2871142/0/en/Cognition-Therapeutics-Completes-Enrollment-in-Phase-2-SHIMMER-Study-of-CT1812-in-Mild-to-Moderate-Dementia-with-Lewy-Bodies.html

    GLOBENEWSWIRE
    29 Apr 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.